May 1st 2024
While 84% of commercials targeted female consumers and 77% utilized celebrity influence, less than half mentioned specific ingredients in skin lightening products.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Rare Cryolipolysis Complications
August 24th 2021When used incorrectly or inaccurately, cryolipolysis can, in rare cases, result in SAEs including dysesthesia, pain, paradoxical adipose hyperplasia, skin blanching, vasovagal reactions, skin hyperpigmentation, contour irregularities, and nerve injuries.
FDA Clears ellacor Micro-Coring Technology for Wrinkles
August 11th 2021Roy Geronemus, MD, clinical professor of dermatology at New York University Medical Center & Dermatology Times editorial advisory board member, discusses the recent FDA clearance of ellacor Micro-Coring Technology for treatment of moderate to severe wrinkles in the mid to lower face.